Astrazeneca (AZN) Goodwill (2016 - 2026)

Astrazeneca has reported Goodwill over the past 18 years, most recently at $21.2 billion for Q1 2026.

For Q1 2026, Goodwill changed 0.3% year-over-year to $21.2 billion; the TTM value through Mar 2026 reached $21.2 billion, changed 0.3%, while the annual FY2025 figure was $21.2 billion, 1.03% up from the prior year.
Goodwill for Q1 2026 was $21.2 billion at Astrazeneca, roughly flat from $21.2 billion in the prior quarter.
Over five years, Goodwill peaked at $21.2 billion in Q4 2025 and troughed at -$313.0 million in Q4 2023.
A 5-year average of $19.3 billion and a median of $20.0 billion in 2023 define the central range for Goodwill.
Biggest five-year swings in Goodwill: tumbled 101.58% in 2023 and later skyrocketed 6817.25% in 2024.
Year by year, Goodwill stood at $19.8 billion in 2022, then tumbled by 101.58% to -$313.0 million in 2023, then skyrocketed by 6817.25% to $21.0 billion in 2024, then rose by 1.03% to $21.2 billion in 2025, then decreased by 0.23% to $21.2 billion in 2026.
Business Quant data shows Goodwill for AZN at $21.2 billion in Q1 2026, $21.2 billion in Q4 2025, and $21.2 billion in Q3 2025.

Peer Comparison